Seaport Therapeutics Raises $100M for Advancing Neuropsychiatric Medicines

Seaport Therapeutics Raises $100M in Series A Funding

Key Highlights:

• Series A Funding: Seaport Therapeutics, a clinical-stage biopharmaceutical company, raised $100 million in Series A funding.
• Investors: The round was co-led by Arch Venture Partners and Sofinnova Investments, along with Third Rock Ventures and Seaport founder PureTech Health.
• Pipeline Advancement: The funding will be used to advance Seaport's clinical-stage pipeline of neuropsychiatric medicines and further develop the Glyph platform.

Seaport Therapeutics' Target Market

• Target Market: Patients with neuropsychiatric conditions in need of novel treatment options.
• Neuropsychiatric Medicine: Focus on developing medicines for conditions such as anxious depression, Generalized Anxiety Disorder, mood disorders, and other neuropsychiatric disorders.
• Advancements in Drug Delivery: Utilizing the Glyph platform to improve oral bioavailability, bypass first-pass metabolism, and reduce side effects.

What Seaport Therapeutics Needs to Buy

• Clinical Research and Development Services: Collaborating with research organizations and clinical trial partners for the advancement of their pipeline.
• Manufacturing and Supply Chain Solutions: Partnering with manufacturers to ensure efficient production and distribution of their medicines.
• Regulatory and Compliance Expertise: Engaging with regulatory consultants and experts to navigate the complex landscape of drug development and approvals.